Clinical trials
Observational Prostatic Neoplasms trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 8 |
| Unknown status | 5 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ipsen | 4 |
| Bayer | 3 |
| Universidad Miguel Hernandez de Elche | 3 |
| Consorci Sanitari de Terrassa | 2 |
| Aesculap AG | 1 |
| Astellas Pharma Europe Ltd. | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| AstraZeneca | 1 |
| Clinica Universidad de Navarra, Universidad de Navarra | 1 |
| EDAP TMS S.A. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 40 |
| Breast Neoplasms | 3 |
| Neoplasms | 3 |
| Lung Neoplasms | 2 |
| Acne Vulgaris | 1 |
| Adenocarcinoma | 1 |
| Alopecia | 1 |
| COVID-19 | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Colonic Neoplasms | 1 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.